- Mibefradil
-
Mibefradil Systematic (IUPAC) name (1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate Clinical data AHFS/Drugs.com Micromedex Detailed Consumer Information MedlinePlus a607007 Pregnancy cat. ? Legal status Withdrawn from market Routes Oral Identifiers CAS number 116644-53-2 ATC code C08CX01 PubChem CID 60662 DrugBank DB01388 UNII 27B90X776A KEGG D08217 ChEMBL CHEMBL45816 Chemical data Formula C29H38FN3O3 Mol. mass 495.63 g/mol (what is this?) (verify) Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.
It is nonselective.[1]
On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market,[2] due to the potential for drug interactions, some of them serious, which may occur when it is taken together with some other medications.
References
- ^ Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636. http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=7565636.
- ^ Letter from Roche Laboratories: http://www.fda.gov/medwatch/SAFETY/1998/poscor.htm
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.